ClinicalTrials.gg
Not yet recruitingNCT07894211Updated Oct 26, 2026

QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

A Phase 3 interventional study of Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen) and QLC5508 in Extrapulmonary Neuroendocrine Carcinoma, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 versus investigator's choice chemotherapy in participants with advanced EP-NEC that has failed after at least one prior platinum-based chemotherapy regimen.

02

Conditions studied

  • Extrapulmonary Neuroendocrine Carcinoma
03

In context

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

This study's planned enrollment of 270 is above the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.

Browse Carcinoma, Neuroendocrine studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily consent to participate in this study and sign the form.
  2. Males and females aged ≥18 years old;
  3. Performance Status (ECOG PS) score of 0 or 1;
  4. Estimated survival time of more than 3 months.
  5. A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of , and the result must be negative and must not be lactating; All enrolled patients and the partners should take adequate barrier during the entire treatment cycle and for 6 months after the end of treatment.
  6. Capable of understanding trial requirements, willing and able to comply with trial and follow-up procedures.
  7. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute- (NCI-CTCAE) version 6.0 (v6.0).
  8. Voluntarily sign the written informed consent form and comply with the protocol requirements.
  9. or cytologically confirmed advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)
  10. Has at least 1 according to (RECIST) version 1.1 (v1.1) as assessed by the investigator.
  11. Sufficient bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of other primary within 5 years prior to signing the form.
  2. Patients diagnosed with Merkel cell carcinoma or medullary thyroid carcinoma.
  3. (unless asymptomatic and no progression confirmed by imaging ≥4 weeks prior to randomization); Presence of or brainstem ; Spinal cord compression (identified via imaging, regardless of symptoms).
  4. Previous or ongoing treatment with topoisomerase I inhibitors
  5. Having previously received B7-H3-targeted therapy.
  6. Insufficient washout of prior anticancer therapies prior to randomization.
  7. Having underwent major organ surgery (excluding ) or significant trauma within 4 weeks prior to randomization; Requiring elective surgery during the study.
  8. Having received or live attenuated vaccine within 4 weeks before study randomization.
  9. Having received treatment with systemic (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other agents within 14 days prior to randomization.
  10. Moderate to severe pulmonary disease significantly impairing lung function, including idiopathic pulmonary fibrosis, /connective tissue disorders with lung involvement, or prior pneumonectomy.
  11. Having a history of interstitial lung disease (ILD)/ non-infectious pneumonitis that required corticosteroids, current ILD/ non-infectious pneumonitis, or suspected ILD/ non-infectious pneumonitis that cannot be ruled out by imaging at screening;
  12. Active tuberculosis; Autoimmune diseases not in clinical remission, other acquired or congenital immunodeficiency diseases; Having a history of allogeneic stem cell, bone marrow, or organ transplantation.
  13. Serious infections (e.g., bacteremia, or severe pneumonia) within 4 weeks prior to randomization; Active infection requiring systemic antibiotic therapy within 1 weeks prior to randomization;
  14. Having positive results in virus serology tests ( virus infection participants receiving antiviral treatment other than interferon are allowed to be enrolled).
  15. Uncontrolled or significant cardiovascular disease.
  16. Clinically uncontrolled third-space effusion.
  17. Drug abuse.
  18. Having alcohol or drug dependence.
  19. Poor compliance as per investigator discretion; Any other medical conditions that may interfere with study participation or the results of the clinical study as per the discretion of investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    QLC5508 group

    Drug: QLC5508

  • Active comparator
    Control group

    Drug: Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen)

Interventions

  • DrugInvestigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen)

    FOLFIRI regimen: Irinotecan 180 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks. FOLFOX regimen: oxaliplatin 85 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks.

  • QLC5508 will be administered intravenously once every 2 weeks. Each treatment cycle is 4 weeks.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the duration from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 48 months

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the duration from the date of randomization to the date of first documented progressive disease (PD) based on investigator assessment, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 48 months

  2. Objective response rate (ORR)

    ORR is defined as the percentage of participants achieved complete response or partial response as assessed according to RECIST v1.1 criteria.

    Time frame: Up to approximately 48 months

  3. Duration of response (DOR)

    DOR is defined as the duration from the first documented objective response to the first documented disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 48 months

  4. Disease control rate (DCR)

    DCR is defined as the percentage of participants achieved complete response, partial response, or stable disease as assessed according to RECIST v1.1 criteria.

    Time frame: Up to approximately 48 months

  5. Treatment Emergent Adverse Event (TEAE)

    TEAEs are defined as any adverse event (AE) that occurs after the initiation of study treatment, or any pre-existing condition that worsens in severity or frequency after the initiation of study treatment, regardless of the causal relationship to the study treatment. TEAEs will be graded and summarized by type, frequency, and severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0.

    Time frame: Up to approximately 48 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2026
First posted
Oct 26, 2026
StartEst.
Oct 26, 2026
Primary completionEst.
Mar 26, 2029
CompletionEst.
Jun 30, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07894211
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Mar 26, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Hong Sun, Bachelor
Contact
hong.sun@qilu-pharma.com
+86-18106583128

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC5508

Start the discussion